|1.||Wang, Jing: 6 articles (04/2015 - 03/2010)|
|2.||Atoyan, Ruzanna: 3 articles (04/2015 - 05/2010)|
|3.||Lai, Cheng-Jung: 3 articles (06/2013 - 03/2010)|
|4.||Cai, Xiong: 3 articles (06/2013 - 03/2010)|
|5.||Ma, Anna W: 2 articles (04/2015 - 06/2013)|
|6.||Voi, Maurizio: 2 articles (10/2014 - 06/2013)|
|7.||Zhai, Hai-Xiao: 2 articles (05/2010 - 03/2010)|
|8.||Yin, Ling: 2 articles (05/2010 - 03/2010)|
|9.||Qian, Changgeng: 2 articles (05/2010 - 03/2010)|
|10.||Bao, Rudi: 2 articles (05/2010 - 03/2010)|
12/15/2014 - "Here, we have investigated the impact of ABCB1 and ABCG2 on the efficacy of CUDC-101 in human cancer cells. "
12/15/2014 - "Recently, in its first in human phase I study, CUDC-101 showed promising single agent activity against advanced solid tumors and favorable pharmacodynamic profile. "
10/01/2014 - "Phase I first-in-human study of CUDC-101, a multitargeted inhibitor of HDACs, EGFR, and HER2 in patients with advanced solid tumors."
12/15/2014 - "We revealed that although CUDC-101 has potent antiproliferative and proapoptotic activities against most cancer cell lines, the overexpression of ABCB1 or ABCG2 in cancer cells significantly reduced the activity of CUDC-101 against HDAC, EGFR and HER2, as well as its cytotoxicity and proapoptotic activity. "
10/01/2014 - "Twenty-five patients with advanced solid tumors received escalating doses of CUDC-101 (range, 75-300 mg/m(2)/day) following a standard 3 + 3 dose escalation design. "
|2.||Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous)
01/01/2014 - "Out of these, more than 8 novel hydroxamic acid based HDACi i.e., belinostat, abexinostat, SB939, resminostat, givinostat, quisinostat, pentobinostat, CUDC-101 are in clinical trials and one of the drug vorinostat (SAHA) has been approved by US FDA for cutaneous T-cell lymphoma (CTCL). "
|3.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
|4.||Squamous Cell Neoplasms (Squamous Cell Cancer)
|5.||Stomach Neoplasms (Stomach Cancer)
|1.||Hydroxamic Acids (Hydroxamic Acid)
|4.||vorinostat (suberoylanilide hydroxamic acid)
|5.||Epidermal Growth Factor Receptor (EGF Receptor)
|6.||Histone Deacetylases (Histone Deacetylase)
|9.||anaplastic Thyroid cancer